Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 Injection in Overweight or Obese Adults
CTR20233008Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in obesity, Overweight, sponsored by Fujian Shengdi Pharmaceuticals. Started Sep 2023; status: completed.
02
Drugs
HRS9531
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20233008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233008.